Helmy Eltoukhy believes a liquid biopsy for early cancer screening could be technologically feasible within one to two years, but clinical studies are the primary gating item.

Guardant Health's liquid biopsy test has a sensitivity of approximately 40% for brain cancers, which is lower than the 85% for most other cancers due to the blood-brain barrier.

Guardant Health's proprietary technology improves the accuracy of DNA sequencing by 1,000 to 10,000-fold compared to off-the-shelf sequencers.